AstraZeneca facing three big investor debates as results loom, says Barclays

AstraZeneca PLC (LSE:AZN) shares have continued their underperformance from the final quarter of last year into January, with Barclays identifying three major debates around the stock ahead of this week's results.  Since hitting an all-time high above £128 per share last April, the shares have fallen more than 19% and in the fourth quarter underperformed the Stoxx Europe 600 health sector by around 6%. The bank noted that this was "due to concerns about next year's numbers being too high", which is a trade ...